United Therapeutics Corporation Proceeds from Maturities, Prepayments and Calls of Held-to-maturity Securities
United Therapeutics Corporation (UTHR) reported Proceeds from Maturities, Prepayments and Calls of Held-to-maturity Securities of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-24.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities · last filed 2022-02-24
- United Therapeutics Corporation proceeds from maturities, prepayments and calls of held-to-maturity securities for the quarter ending 2020-12-31 was $0.00.
- United Therapeutics Corporation proceeds from maturities, prepayments and calls of held-to-maturity securities for the quarter ending 2020-09-30 was $0.00, a 100.00% decline year-over-year.
- United Therapeutics Corporation proceeds from maturities, prepayments and calls of held-to-maturity securities for the quarter ending 2019-12-31 was $0.00, a 100.00% decline year-over-year.
- United Therapeutics Corporation proceeds from maturities, prepayments and calls of held-to-maturity securities for the quarter ending 2019-09-30 was $1.50M, a 94.09% decline year-over-year.
- United Therapeutics Corporation proceeds from maturities, prepayments and calls of held-to-maturity securities for fiscal 2021 was $0.00.
- United Therapeutics Corporation proceeds from maturities, prepayments and calls of held-to-maturity securities for fiscal 2020 was $0.00, a 100.00% decline from fiscal 2019.
- United Therapeutics Corporation proceeds from maturities, prepayments and calls of held-to-maturity securities for fiscal 2019 was $39.70M, a 55.19% decline from fiscal 2018.
- United Therapeutics Corporation proceeds from maturities, prepayments and calls of held-to-maturity securities for fiscal 2018 was $88.60M, a 67.49% increase from fiscal 2017.
| Period end | Proceeds from Maturities, Prepayments and Calls of Held-to-maturity Securities 3 month | Proceeds from Maturities, Prepayments and Calls of Held-to-maturity Securities 3 month as first filed | Proceeds from Maturities, Prepayments and Calls of Held-to-maturity Securities 6 month | Proceeds from Maturities, Prepayments and Calls of Held-to-maturity Securities 6 month as first filed | Proceeds from Maturities, Prepayments and Calls of Held-to-maturity Securities 9 month | Proceeds from Maturities, Prepayments and Calls of Held-to-maturity Securities 9 month as first filed | Proceeds from Maturities, Prepayments and Calls of Held-to-maturity Securities 12 month | Proceeds from Maturities, Prepayments and Calls of Held-to-maturity Securities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2021-12-31 | $0.00 10-K · filed 2022-02-24 | |||||||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $0.00 derived: sum of 2 quarters · filed 2022-02-24 | $0.00 10-K · filed 2022-02-24 | |||||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-28 | $0.00 10-Q · filed 2020-10-28 | ||||||
| 2020-06-30 | $0.00 10-Q · filed 2020-07-29 | |||||||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $1.50M derived: sum of 2 quarters · filed 2022-02-24 | $2.30M derived: sum of 3 quarters · filed 2022-02-24 | $39.70M 10-K · filed 2022-02-24 | ||||
| 2019-09-30 | $1.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-28 | $2.30M derived: sum of 2 quarters · filed 2020-10-28 | $39.70M 10-Q · filed 2020-10-28 | $75.30M derived: sum of 4 quarters · filed 2021-02-24 | ||||
| 2019-06-30 | $800.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-29 | $38.20M 10-Q · filed 2020-07-29 | $73.80M derived: sum of 3 quarters · filed 2021-02-24 | $99.20M derived: sum of 4 quarters · filed 2021-02-24 | ||||
| 2019-03-31 | $37.40M 10-Q · filed 2020-04-29 | $73.00M derived: sum of 2 quarters · filed 2021-02-24 | $98.40M derived: sum of 3 quarters · filed 2021-02-24 | $99.20M derived: sum of 4 quarters · filed 2021-02-24 | ||||
| 2018-12-31 | $35.60M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $61.00M derived: sum of 2 quarters · filed 2021-02-24 | $61.80M derived: sum of 3 quarters · filed 2021-02-24 | $88.60M 10-K · filed 2021-02-24 | ||||
| 2018-09-30 | $25.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-30 | $26.20M derived: sum of 2 quarters · filed 2019-10-30 | $53.00M 10-Q · filed 2019-10-30 | $53.30M derived: sum of 4 quarters · filed 2020-02-26 | ||||
| 2018-06-30 | $800.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-31 | $27.60M 10-Q · filed 2019-07-31 | $27.90M derived: sum of 3 quarters · filed 2020-02-26 | $54.40M derived: sum of 4 quarters · filed 2020-02-26 | ||||
| 2018-03-31 | $26.80M 10-Q · filed 2019-05-01 | $27.10M derived: sum of 2 quarters · filed 2020-02-26 | $53.60M derived: sum of 3 quarters · filed 2020-02-26 | $58.90M derived: sum of 4 quarters · filed 2020-02-26 | ||||
| 2017-12-31 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26 | $26.80M derived: sum of 2 quarters · filed 2020-02-26 | $32.10M derived: sum of 3 quarters · filed 2020-02-26 | $52.90M 10-K · filed 2020-02-26 | ||||
| 2017-09-30 | $26.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-31 | $31.80M derived: sum of 2 quarters · filed 2018-10-31 | $52.60M 10-Q · filed 2018-10-31 | $104.20M derived: sum of 4 quarters · filed 2019-02-27 | ||||
| 2017-06-30 | $5.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-01 | $26.10M 10-Q · filed 2018-08-01 | $77.70M derived: sum of 3 quarters · filed 2019-02-27 | $106.90M derived: sum of 4 quarters · filed 2019-02-27 | ||||
| 2017-03-31 | $20.80M 10-Q · filed 2018-05-02 | $72.40M derived: sum of 2 quarters · filed 2019-02-27 | $101.60M derived: sum of 3 quarters · filed 2019-02-27 | $130.20M derived: sum of 4 quarters · filed 2019-02-27 | ||||
| 2016-12-31 | $51.60M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $80.80M derived: sum of 2 quarters · filed 2019-02-27 | $109.40M derived: sum of 3 quarters · filed 2019-02-27 | $130.40M 10-K · filed 2019-02-27 | ||||
| 2016-09-30 | $29.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-25 | $57.80M derived: sum of 2 quarters · filed 2017-10-25 | $78.80M 10-Q · filed 2017-10-25 | $166.80M derived: sum of 4 quarters · filed 2018-02-21 | ||||
| 2016-06-30 | $28.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-07-27 | $49.60M 10-Q · filed 2017-07-27 | $137.60M derived: sum of 3 quarters · filed 2018-02-21 | $197.20M derived: sum of 4 quarters · filed 2018-02-21 | ||||
| 2016-03-31 | $21.00M 10-Q · filed 2017-04-26 | $109.00M derived: sum of 2 quarters · filed 2018-02-21 | $168.60M derived: sum of 3 quarters · filed 2018-02-21 | $244.70M derived: sum of 4 quarters · filed 2018-02-21 | ||||
| 2015-12-31 | $88.00M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-21 | $147.60M derived: sum of 2 quarters · filed 2018-02-21 | $223.70M derived: sum of 3 quarters · filed 2018-02-21 | $320.40M 10-K · filed 2018-02-21 | $320.37M 10-K · filed 2016-02-25 | |||
| 2015-09-30 | $59.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-10-27 | $135.70M derived: sum of 2 quarters · filed 2016-10-27 | $232.40M 10-Q · filed 2016-10-27 | $232.42M 10-Q · filed 2015-10-27 | $290.17M derived: sum of 4 quarters · filed 2017-02-22 | |||
| 2015-06-30 | $76.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-07-28 | $172.80M 10-Q · filed 2016-07-28 | $172.82M 10-Q · filed 2015-07-28 | $230.57M derived: sum of 3 quarters · filed 2017-02-22 | $347.24M derived: sum of 4 quarters · filed 2017-02-22 | |||
| 2015-03-31 | $96.70M 10-Q · filed 2016-04-28 | $96.70M 10-Q · filed 2015-04-28 | $154.47M derived: sum of 2 quarters · filed 2017-02-22 | $271.14M derived: sum of 3 quarters · filed 2017-02-22 | $411.18M derived: sum of 4 quarters · filed 2017-02-22 | |||
| 2014-12-31 | $57.77M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-22 | $174.44M derived: sum of 2 quarters · filed 2017-02-22 | $314.48M derived: sum of 3 quarters · filed 2017-02-22 | $549.60M 10-K · filed 2017-02-22 | $549.58M 10-K · filed 2015-02-24 | |||
| 2014-09-30 | $116.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-10-27 | $256.71M derived: sum of 2 quarters · filed 2015-10-27 | $491.83M 10-Q · filed 2015-10-27 | $672.46M derived: sum of 4 quarters · filed 2016-02-25 | ||||
| 2014-06-30 | $140.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-07-28 | $375.16M 10-Q · filed 2015-07-28 | $555.79M derived: sum of 3 quarters · filed 2016-02-25 | $665.55M derived: sum of 4 quarters · filed 2016-02-25 | ||||
| 2014-03-31 | $235.13M 10-Q · filed 2015-04-28 | $415.75M derived: sum of 2 quarters · filed 2016-02-25 | $525.51M derived: sum of 3 quarters · filed 2016-02-25 | $638.40M derived: sum of 4 quarters · filed 2016-02-25 | ||||
| 2013-12-31 | $180.63M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-25 | $290.39M derived: sum of 2 quarters · filed 2016-02-25 | $403.28M derived: sum of 3 quarters · filed 2016-02-25 | $529.90M 10-K · filed 2016-02-25 | ||||
| 2013-09-30 | $109.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-28 | $222.65M derived: sum of 2 quarters · filed 2014-10-28 | $349.27M 10-Q · filed 2014-10-28 | $437.15M derived: sum of 4 quarters · filed 2015-02-24 | ||||
| 2013-06-30 | $112.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-07-29 | $239.51M 10-Q · filed 2014-07-29 | $327.38M derived: sum of 3 quarters · filed 2015-02-24 | $438.31M derived: sum of 4 quarters · filed 2015-02-24 | ||||
| 2013-03-31 | $126.62M 10-Q · filed 2014-04-29 | $214.49M derived: sum of 2 quarters · filed 2015-02-24 | $325.42M derived: sum of 3 quarters · filed 2015-02-24 | $476.77M derived: sum of 4 quarters · filed 2015-02-24 | ||||
| 2012-12-31 | $87.87M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-24 | $198.80M derived: sum of 2 quarters · filed 2015-02-24 | $350.14M derived: sum of 3 quarters · filed 2015-02-24 | $527.86M 10-K · filed 2015-02-24 | ||||
| 2012-09-30 | $110.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-29 | $262.27M derived: sum of 2 quarters · filed 2013-10-29 | $439.99M 10-Q · filed 2013-10-29 | $654.53M derived: sum of 4 quarters · filed 2014-02-25 | ||||
| 2012-06-30 | $151.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-07-25 | $329.06M 10-Q · filed 2013-07-25 | $543.60M derived: sum of 3 quarters · filed 2014-02-25 | $756.62M derived: sum of 4 quarters · filed 2014-02-25 | ||||
| 2012-03-31 | $177.71M 10-Q · filed 2013-04-25 | $392.26M derived: sum of 2 quarters · filed 2014-02-25 | $605.28M derived: sum of 3 quarters · filed 2014-02-25 | $767.34M derived: sum of 4 quarters · filed 2014-02-25 | ||||
| 2011-12-31 | $214.54M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-25 | $427.56M derived: sum of 2 quarters · filed 2014-02-25 | $589.63M derived: sum of 3 quarters · filed 2014-02-25 | $733.88M 10-K · filed 2014-02-25 | ||||
| 2011-09-30 | $213.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-01 | $375.08M derived: sum of 2 quarters · filed 2012-11-01 | $519.33M 10-Q · filed 2012-11-01 | $630.51M derived: sum of 4 quarters · filed 2013-02-26 | ||||
| 2011-06-30 | $162.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-07-26 | $306.31M 10-Q · filed 2012-07-26 | $417.49M derived: sum of 3 quarters · filed 2013-02-26 | $530.99M derived: sum of 4 quarters · filed 2013-02-26 | ||||
| 2011-03-31 | $144.25M 10-Q · filed 2012-04-26 | $255.43M derived: sum of 2 quarters · filed 2013-02-26 | $368.93M derived: sum of 3 quarters · filed 2013-02-26 | $474.48M derived: sum of 4 quarters · filed 2013-02-26 | ||||
| 2010-12-31 | $111.18M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-26 | $224.68M derived: sum of 2 quarters · filed 2013-02-26 | $330.23M derived: sum of 3 quarters · filed 2013-02-26 | $421.53M 10-K · filed 2013-02-26 | ||||
| 2010-09-30 | $113.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-27 | $219.05M derived: sum of 2 quarters · filed 2011-10-27 | $310.35M 10-Q · filed 2011-10-27 | $376.33M derived: sum of 4 quarters · filed 2012-02-28 | ||||
| 2010-06-30 | $105.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-07-28 | $196.85M 10-Q · filed 2011-07-28 | $262.83M derived: sum of 3 quarters · filed 2012-02-28 | $331.15M derived: sum of 4 quarters · filed 2012-02-28 | ||||
| 2010-03-31 | $91.30M 10-Q · filed 2011-04-28 | $157.28M derived: sum of 2 quarters · filed 2012-02-28 | $225.60M derived: sum of 3 quarters · filed 2012-02-28 | |||||
| 2009-12-31 | $65.98M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-28 | $134.30M derived: sum of 2 quarters · filed 2012-02-28 | $249.08M 10-K · filed 2012-02-28 | |||||
| 2009-09-30 | $68.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2010-10-28 | $183.10M 10-Q · filed 2010-10-28 | ||||||
| 2009-06-30 | $114.78M 10-Q · filed 2010-07-28 | |||||||
| 2008-12-31 | $266.05M 10-K · filed 2011-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |